Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Spatial and anatomic parameters from SD-OCT and associations with best corrected visual acuity (BCVA) in ABCA4-associated Stargardt Disease (STGD1)
Author Affiliations & Notes
  • Xiangrong Kong
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Yanzhao WANG
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Folahan Adesola Ibukun
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • David G Birch
    Retina Foundation of the Southwest, Dallas, Texas, United States
  • Elias Traboulsi
    Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States
  • Janet S Sunness
    Greater Baltimore Medical Center, Baltimore, Maryland, United States
  • Paul S Bernstein
    Moran Eye Center, University of Utah Health, Salt Lake City, Utah, United States
  • Isabelle S Audo
    Institut de la vision, Paris, Île-de-France, France
  • Michel Michaelides
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • SriniVas R Sadda
    Doheny Eye Institute, Los Angeles, California, United States
  • Hendrik P Scholl
    Institute of Molecular and Clinical Ophthalmology Basel, Basel, Basel-Stadt, Switzerland
  • Eberhart Zrenner
    Eberhard Karls Universitat Tubingen, Tubingen, Baden-Württemberg, Germany
  • Michael S Ip
    Doheny Eye Institute, Los Angeles, California, United States
  • Sheila K West
    Johns Hopkins Medicine Wilmer Eye Institute, Baltimore, Maryland, United States
  • Artur V Cideciyan
    Scheie Eye Institute, Philadelphia, Pennsylvania, United States
  • Rupert Strauss
    Department of Ophthalmology, Medizinische Universitat Graz, Graz, Steiermark, Austria
  • Footnotes
    Commercial Relationships   Xiangrong Kong None; Yanzhao WANG None; Folahan Ibukun None; David Birch Nacuity Pharmaceuticals, Editas, AGTC, PYC Therapeutics, ONL Therapeutics, Bluerock Therapeutics, Aldyra Novartis, 4D Molecular Therapeutics, Inc., Foundation Fighting Blindness, Code C (Consultant/Contractor), Biogen, AGTC, 4D Molecular Therapeutics Inc, PYC Therapeutics, Ocugen, Code F (Financial Support); Elias Traboulsi Travere Therapeutics, Code C (Consultant/Contractor), Sparing Vision, Code S (non-remunerative); Janet Sunness Lineage(OpRegen trial), Re-Vision Therapeutics , Code S (non-remunerative); Paul Bernstein None; Isabelle Audo Novartis, Janssen, Code C (Consultant/Contractor); Michel Michaelides MeiraGTx, Stargazer, Belite Bio, Mogrify, Code C (Consultant/Contractor), MeiraGTx, Code I (Personal Financial Interest), Stargazer, Belite Bio, MeiraGTx-Janssen, Code S (non-remunerative); SriniVas Sadda Apellis, Amgen, Abbvie/Allergan, Alexion, Samsung Bioepis, Biogen, Boerhinger Ingelheim, IvericBio, Novartis, Roche, Bayer, Regeneron, Pfizer, Astellas, Nanoscope, Jannsen, Centervue, Optos, Heidelberg NotalVision, Eyepoint, Character, OTx, Code C (Consultant/Contractor), Novartis, Roche, Optos, Heidelberg , Code R (Recipient), ARVO, Macula Scoiety, Code S (non-remunerative); Hendrik Scholl Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics., Code C (Consultant/Contractor), Swiss National Science Foundation, the Wellcome Trust, the Foundation Fighting Blindness Clinical Research Institute, Code F (Financial Support), Ascidian Therapeutics, Inc.; Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc,Belite Bio, F. Hoffmann-La Roche Ltd, ViGeneron, Steering Committee of Novo Nordisk , Code S (non-remunerative); Eberhart Zrenner None; Michael Ip Alimera, Allergan, Amgen, Apellis, Clearside Biomedical, Genentech, IVERIC Bio, Novartis, Regeneron, Regenxbio, Code C (Consultant/Contractor), Apellis, Biogen, Genentech, IVERIC Bio, Lineage Cell Therapeutics, ONL Therapeutics, Regenxbio, 4DMT, Code F (Financial Support); Sheila West None; Artur Cideciyan None; Rupert Strauss None
  • Footnotes
    Support  R21EY032955
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2374. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiangrong Kong, Yanzhao WANG, Folahan Adesola Ibukun, David G Birch, Elias Traboulsi, Janet S Sunness, Paul S Bernstein, Isabelle S Audo, Michel Michaelides, SriniVas R Sadda, Hendrik P Scholl, Eberhart Zrenner, Michael S Ip, Sheila K West, Artur V Cideciyan, Rupert Strauss; Spatial and anatomic parameters from SD-OCT and associations with best corrected visual acuity (BCVA) in ABCA4-associated Stargardt Disease (STGD1). Invest. Ophthalmol. Vis. Sci. 2024;65(7):2374.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare retinal layer losses and assess structure function relationship between SD-OCT parameters and BCVA.

Methods : Baseline data collected in the multicenter natural history ProgStar Study were analyzed. From Heidelberg SD-OCT images, retinal pigment epithelium (RPE), outer segment (OS), inner segment (IS), outer nuclear layer (ONL), and inner retina were segmented. ETDRS grid centered at the fovea was overlaid, and thickness of each layer was measured in the center subfield, inner ring, and outer ring. SD-OCT images of 20 normal eyes were also segmented. z-scores measuring the deviation from normal were calculated by layer and region for study eyes. Random effects model was used to compare the z-scores of layers. For the subgroup of eyes with relatively normal RPE thickness, defined as RPE z-score> -1, z-scores were summarized.

Results : There were 259 participants (487 study eyes) aged 7-69 years (54% women). Mean BCVA was 46 (SD=16) letters. Table 1a shows the mean/SD of thicknesses and z-scores by layer/region. All outer retinal layers had significant thinning. The IS showed greatest deviation from normal (mean Z-score -15 in the center and -12 in the inner ring). In both center and inner ring, mean z-scores of the IS and ONL were significantly lower than that of the RPE (p<.001). Mean Z-core of the OS was comparable to that of RPE in the center, but better than RPE in the inner ring. In the subgroups of eyes with relatively normal RPE thickness, all outer retinal layers showed significant thinning (Table 1b). Spearman correlation of BCVA with thicknesses in the center ranged from 0.46 to 0.63; with thickness in the inner ring ranged from 0.34 to 0.38. Figure 1 shows z-scores distributions by BCVA level.

Conclusions : Thinning of outer retinal layers is more pronounced in the center than in the Inner Ring, conforming to the predominantly central involvement known in STGD1. Thinning of the IS exceeds that of the RPE, suggesting that photoreceptor degeneration may occur more rapidly than RPE loss. In subgroups with relatively normal RPE thickness, significant deviations from normal exists in all layers, indicating photoreceptor degeneration may commence early and not necessarily second to RPE loss. Thinning of outer retina layers varied by BCVA level, generally with more thinning associated with more visual impairment.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×